Abstract:Hemoglobinopathies, including thalassemias and sickle cell disease, are the most common monogenic diseases worldwide, with estimated annual births of more than 330,000 affected infants. Hemoglobin disorders account for about 3.4% of deaths in children under 5 years of age. The distribution of these diseases is historically linked to current or previously malaria-endemic regions; however, immigration has led to a worldwide distribution of these diseases, making them a global health problem. During the last decade, new treatment approaches and novel therapies have been proposed, some of which have the potential to change the natural history of these disorders. Indeed, the first erythroid maturation agent, luspatercept, and gene therapy have been approved for beta-thalassemia adult patients. For sickle cell disease, molecules targeting vaso-occlusion and hemoglobin S polymerization include crizanlizumab, which has been approved for patients ≥ 16 years, voxelotor approved for patients ≥ 12 years, and L-glutamine for patients older than 5 years. Conclusion: We herein present the most recent advances and future perspectives in thalassemia and sickle cell disease treatment, including new drugs, gene therapy, and gene editing, and the current clinical trial status in the pediatric populations. What is Known: • Red blood cell transfusions, iron chelation therapy and hematopoietic stem cell transplantation have been the mainstay of treatment of thalassemia patients for decades. • For sickle cell disease, until 2005, treatment strategies were mostly the same as those for thalassemia, with the option of simple transfusion or exchange transfusion. In 2007, hydroxyurea was approved for patients ≥ 2 years old. What is New: • In 2019, gene therapy with betibeglogene autotemcel (LentiGlobin BB305) was approved for TDT patients ≥ 12 years old non β0/β0 without matched sibling donor. • Starting from 2017 several new drugs, such as L-glutamine (approved only by FDA), crizanlizumab (approved by FDA and EMA for patients ≥ 16 years), and lastly voxelotor (approved by FDA and EMA for patients ≥ 12 years old).

Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production

Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia

Novel Therapeutic Approaches In Thalassemias, Sickle Cell Disease And Other Red Cell Disorders

Investigational drugs in phase I and phase II clinical trials for thalassemia

Rise of the planet of rare anemias: An update on emerging treatment strategies

Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia

Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice

Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts

Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell Disease

Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS

Elevating fetal hemoglobin - recently discovered regulators and mechanisms

[Overview of new approaches to β-thalassemia treatment]

An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia

Modulation of the allosteric and vasoregulatory arms of erythrocytic oxygen transport

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation

Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes

A Review of Gene Therapies for Hemoglobinopathies

Activin receptor ligand traps in chronic kidney disease

From Biological Bases to New Possible Therapeutic Strategies

Fetal Hemoglobin Regulation in Beta-Thalassemia

Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease